For In Vitro Diagnostic Use.
The MicroVue DPD EIA offers a laboratory test that measures deoxypyridinoline cross-links (Dpd), a specific marker of bone resorption which is excreted in the urine. MicroVue DPD EIA provides a quantitative measure of deoxypyridinoline (Dpd), a cross-link of bone type 1 collagen released during the resorption process. Dpd is excreted unmetabolized in urine. Elevated levels of urinary Dpd indicate elevated bone resorption in individuals. MicroVue DPD is a urinary ***** that provides a quantitative measure of the excretion of deoxypyridinoline (DPD) crosslinks as an indicator of bone resorption. Elevated levels of urinary DPD indicate elevated bone resorption in individuals.
Measurement of DPD is intended for use as an aid in monitoring bone resorption changes in postmenopausal women receiving hormonal or bisphosphonate antiresorptive therapies and in individuals diagnosed with osteoporosis.
Method: Competitive
Analyte: Deoxypyridinoline cross-links
Specimen: Urine
Specimen Volume: 50 μL
Sensitivity: 1.1 nM/L
Dynamic Range: 3-300 nM
Precision CVs within-run: 4%-8%
Precision CVs between-run: 3%-5%
Incubation Time: 3 Hours
Cross-reactivity:
Free Dpd 100%
Free Pyd: < 1%
Pyd/Dpd peptides: < 2.5%
Expected Values:
Females: 25-44 yr. premenopausal: 3.0-7.4 nmol Dpd/mmol Cr
Males: 25-55 yr.: 2.3-5.4 nmol Dpd/mmol Cr
96-well microplate with reagents sufficient to test 40 samples in duplicate
Rat, Mouse, Rabbit, Guinea Pig, Dog, Pig, Sheep, Cow, Horse, Squirrel, Cynomolgus Monkey, Rhesus Macaque, Human Cell Culture